Following ongoing questions about a budget shortfall at the Oklahoma State Department of Mental Health and Substance Abuse ...

BridgeBio's valuation relies on the commercialization of Attruby, but the drug's full potential may be undermined by tafamidis’ patent extension, introduction of generic alternatives, and other ...

Total operating loss from continuing operations increased from $6.6 million in 2023 to $6.9 million in 2024. Research and ...

Three men share their struggles with finding employment and housing after prison and call for better reentry support in ...

Debroah Frisbie is one of thousands of family members raising relative foster care children in Michigan, asking for more ...

The patent includes 58 claims related to the formulations’ purity and stability, as well as methods ... preventing the conversion to inactive forms of the drug. The company continues to advance ...

Blue Cross Blue Shield of Vermont (BCBSVT) faced financial difficulties due to rising hospital and prescription drug costs ... and ensure long-term stability of our organization and our health ...

InvestingPro subscribers have access to over 10 additional key insights about OKYO’s financial ... has announced that its drug candidate, urcosimod, has demonstrated stability for over two ...

InvestingPro subscribers have access to over 10 additional key insights about OKYO’s financial health ... OKYO Pharma Limited has announced that its drug candidate, urcosimod, has demonstrated ...

If you’re after a defensive stock, consider Loblaw Companies ( TSX:L ). Everyone needs groceries, and Loblaw has a strong grip on Canada’s food retail market through brands like Loblaws, Real Canadian ...

The patent includes 58 claims related to the formulations’ purity and stability, as well as methods for their use ... preventing the conversion to inactive forms of the drug. The company continues to ...